A non-thermal laser therapy, Retinal Rejuvenation Therapy (2RT®) stimulates a natural, biological healing response in the eye and in a pilot study on 50 patients has demonstrated potential as an intervention which may positively influence early Age-Related Macular Degeneration (eAMD).
Research conducted by Prof. John Marshall and colleagues suggests that the nanosecond laser pulse modality of 2RT® may delay pathological and molecular changes in AMD. According to Prof. Marshall, treatment with 2RT® may help to improve early-stage AMD by cleaning up the debris in Bruch’s membrane. However, the ultimate goal of 2RT is to prevent the progression of AMD to its late stages.
“… if we can slow down the basal rate of Bruch’s membrane aging and restore function to what it was when the patient was in their teens, we should be able to significantly delay AMD onset.”